Table 1.

Instruments used to evaluate the efficacy of rivastigmine in treating Alzheimer’s disease

Instrument	Symptoms or domains assessed	Source of information	Range of scale and interpretation
Alzheimer’s disease assessment scale (cognitive subscale)	Cognition (memory, language, orientation, praxis)	Patient	0-70 points 0=no errors (rarely achieved, even in general population) 70=severe impairment
Clinician interview based impression of change scale (incorporating caregiver information)	Global assessment of behaviour, general psychopathology, cognition, and activities of daily living	Patient and caregiver during interview with clinician*	1-7 points 1, 2, 3=marked, moderate, or minimal improvement 4=no change 5, 6, 7=minimal, moderate, or marked deterioration
Progressive deterioration scale	Activities of daily living (dressing and eating independently, social interaction, participation in housework and hobbies, awareness of time, handling of financial matters)	Caregiver	29 items Scores range from 0 to 100

^*Clinicians had no access to data on efficacy or safety.